2022
Rationale, Design, and Characteristics of the VALIANT (COVID‐19 in Older Adults: A Longitudinal Assessment) Cohort
Cohen A, McAvay G, Geda M, Chattopadhyay S, Lee S, Acampora D, Araujo K, Charpentier P, Gill T, Hajduk A, Ferrante L. Rationale, Design, and Characteristics of the VALIANT (COVID‐19 in Older Adults: A Longitudinal Assessment) Cohort. Journal Of The American Geriatrics Society 2022, 71: 832-844. PMID: 36544250, PMCID: PMC9877652, DOI: 10.1111/jgs.18146.Peer-Reviewed Original ResearchConceptsPatient-centered outcomesCOVID-19 hospitalizationCognitive impairmentPhysical functionOlder COVID-19 survivorsCOVID-19-related symptomsCOVID-19Older adultsIntensive care unitCOVID-19 survivorsPersistent cognitive impairmentSix-month followMost older adultsThird of participantsElectronic health recordsStepdown unitAcute illnessBurdensome symptomsCare unitSupplemental oxygenMedian lengthProspective studyMean ageBlack raceBaseline interview
2017
Guideline‐Recommended Medications and Physical Function in Older Adults with Multiple Chronic Conditions
McAvay G, Allore HG, Cohen AB, Gnjidic D, Murphy TE, Tinetti ME. Guideline‐Recommended Medications and Physical Function in Older Adults with Multiple Chronic Conditions. Journal Of The American Geriatrics Society 2017, 65: 2619-2626. PMID: 28905359, PMCID: PMC5729049, DOI: 10.1111/jgs.15065.Peer-Reviewed Original ResearchConceptsGuideline-recommended medicationsMultiple chronic conditionsCoronary artery diseasePhysical functionChronic conditionsHeart failureAtrial fibrillationSelf-reported declineOlder adultsArtery diseaseDiabetes mellitusRenin-angiotensin system blockersAngiotensin system blockersProspective observational cohortCommunity-dwelling adultsHealth risk factorsOverall sampleLess polypharmacyPolypharmacy exposureSystem blockersObservational cohortSingle medicationRisk factorsMedicationsLower risk